[Federal Register Volume 67, Number 44 (Wednesday, March 6, 2002)]
[Notices]
[Page 10137]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 02-5249]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Availability for Non-Exclusive, Exclusive, or Partially Exclusive 
Licensing of U.S. Patent Concerning Mutants of Brucella Melitensis

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 37 CFR 404.6, announcement is made of the 
availability for licensing of U.S. Patent No. 5,939,075 entitled 
``Mutants of Brucella Melitensis'' issued August 17, 1999. The United 
States Government as represented by the Secretary of the Army has 
rights in this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, Maryland 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research & Technology Assessment, (301) 619-6664, both 
at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The vaccines are prepared by isolating the 
Brucella genes complementing mutations in the purEK genes of 
Escherichia coli, physically mapping, determining the DNA sequence, 
constructing a defined deletion mutation by polynucleotide chain 
reaction (PCR), introducing a selectable marker into the deletion, and 
then selecting a purE mutant in Brucella arising by allelic exchange. 
The resulting Brucella require purines for growth because they lack the 
pure gene product that is required for the carboxylation of 5'-
phosphoribosyl-5-aminoimidazole.

Luz D. Ortiz,
Army Federal Register Liaison Officer.
[FR Doc. 02-5249 Filed 3-5-02; 8:45 am]
BILLING CODE 3710-08-M